Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by...

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Death Signaling

Background:

• Tumors with Bcl-2 overexpression or defective Bax/Bak impair mitochondrial cytochrome c release and caspase activation, hindering apoptosis.
• Directly triggering cell death downstream of Bax and Bak is a promising strategy for overcoming cancer resistance.
• Existing cell-free systems for screening direct caspase activators lack crucial cellular components for accurate validation.

Purpose of the Study:

• To develop and validate precise cell-based models for screening direct caspase-activating compounds.
• To investigate the mechanism of action of PAC-1, a known procaspase-activating compound.
• To establish criteria for validating direct caspase activators in cancer cells.

Main Methods:

• Development of refined cell-based assays to validate direct caspase activation.
• Utilizing cancer cell lines with specific genetic modifications (e.g., Bax/Bak deficiency, Bcl-2 overexpression).
• Assessing caspase activation and cell death induction by PAC-1 in these cellular models.

Main Results:

• PAC-1, identified in cell-free systems, requires mitochondrial cytochrome c release for caspase activation in cell-based models.
• PAC-1 effectively induces caspase activation and cell death in cancer cells lacking Bax and Bak.
• PAC-1 demonstrates efficacy in cells overexpressing Bcl-2 and Bcl-xL, suggesting a mechanism independent of these proteins.

Conclusions:

• The developed cell-based models provide precise criteria for validating direct caspase-activating compounds.
• PAC-1's mechanism highlights the importance of mitochondrial pathways even for direct caspase activators.
• This approach is expected to accelerate the discovery of novel anti-cancer therapeutics targeting cell death pathways.